Andere Sprachen 89bio, Inc.

Aktien

A2PUP8

US2825591033

ETNB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.05.2024			% 5 Tage	% 1. Jan.
8,93 ^USD	-0,22 %		-2,93 %	-20,05 %

14.05.	89Bio startet Phase-3-Studie Enlighten-Cirrhosis mit Pegozafermin bei Patienten mit metabolischer Dysfunktion und kompensierter Steatohepatitis (MASH)	CI
10.05.	89BIO, INC. : HC Wainwright behält seine Kaufempfehlung bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress	22.05.
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis	14.05.
89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	14.05.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	10.05.
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	09.05.
89bio to Participate in the BofA Securities 2024 Health Care Conference	08.05.
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH	02.05.
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17.04.
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17.04.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05.04.
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03.04.
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27.03.
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27.03.
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27.03.
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27.03.
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27.03.
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12.03.
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12.03.
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen 89bio, Inc.

Aktien

A2PUP8

US2825591033

ETNB

Andere Sprachen

Filter